Innoviva, Inc.

NASDAQ:INVA

20.48 (USD) • At close September 5, 2025
Bedrijfsnaam Innoviva, Inc.
Symbool INVA
Munteenheid USD
Prijs 20.48
Beurswaarde 1,290,670,080
Dividendpercentage 0%
52-weken bereik 16.67 - 22
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pavel Raifeld C.F.A.
Website https://www.inva.com

An error occurred while fetching data.

Over Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium

Vergelijkbare Aandelen

Adaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation

ADPT

12.85 USD

SomaLogic, Inc. logo

SomaLogic, Inc.

SLGC

2.1 USD

Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

ALLO

1.15 USD

Instil Bio, Inc. logo

Instil Bio, Inc.

TIL

31.5 USD

NGM Biopharmaceuticals, Inc. logo

NGM Biopharmaceuticals, Inc.

NGM

1.54 USD

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

36.01 USD

RadNet, Inc. logo

RadNet, Inc.

RDNT

71.41 USD

Outset Medical, Inc. logo

Outset Medical, Inc.

OM

14.01 USD

Celularity Inc. logo

Celularity Inc.

CELU

2.41 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)